Page last updated: 2024-11-12

n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide: a vanilloid receptor 1 antagonist and analgesic; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9929425
CHEMBL ID441472
CHEBI ID190962
SCHEMBL ID1269620
MeSH IDM0451932

Synonyms (34)

Synonym
n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide
gtpl2460
bctc
n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
bctc cpd
4-(3-chloro-pyridin-2-yl)-piperazine-1-carboxylic acid (4-tert-butyl-phenyl)-amide
bdbm50133817
CHEMBL441472 ,
1-piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]-
CHEBI:190962
4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide, bctc
mfcd08690556
393514-24-4
S6838
SCHEMBL1269620
4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide
HB1190
AKOS024457842
c20h25cln4o
DTXSID90432997
FT-0696667
HY-19960
CS-5476
n-(4-t-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide
AS-73732
bctc, >=98% (hplc)
NCGC00370959-01
BCP19629
Q27074955
CCG-356434
n-(4-(tert-butyl)phenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
EX-A4527
A912829
BB165272

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" BCTC was orally bioavailable in the rat, demonstrating a plasma half-life of approximately 1 h and significant penetration into the central nervous system."( N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
Francis, J; Grant, ER; Hachicha, M; Hodges, D; Limberis, J; Malik, S; Rotshteyn, Y; Schmid, L; Sun, Q; Tafesse, L; Valenzano, KJ; Whittemore, ER; Wu, G, 2003
)
0.32
" This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner."( Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Balan, C; Bannon, AW; Bo, Y; Dominguez, C; Fotsch, C; Gavva, NR; Gore, VK; Klionsky, L; Ma, VV; Norman, MH; Ognyanov, VI; Qian, YX; Tamir, R; Treanor, JJ; Wang, X; Xi, N; Xu, S; Zhu, D, 2006
)
0.33
" However, its use is limited by the low bioavailability and irritating quality."( Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
Gao, M; Li, J; Nie, C; Qian, H; Song, B; Yan, L, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" This compound penetrates the CNS and shows potent anti-nociceptive effects in a broad range of animal pain models upon oral dosing due in part to its ability to antagonize both central and peripheral TRPV1 receptors."( Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Bianchi, BR; Brown, BS; Faltynek, CR; Honore, P; Jarvis, MF; Keddy, R; Koenig, JR; Lee, CH; Marsh, KC; McDonald, HA; Polakowski, JS; Schmidt, RG; Surowy, CS; Zheng, GZ, 2008
)
0.35
"9nM) showed a good pharmacokinetic profile upon oral dosing at 10mg/kg in Sprague-Dawley (SD) rats."( Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides as TRPM8 antagonists.
Bhosale, VM; Chaudhari, SS; Gudi, GS; Kadam, AB; Karnik, PV; Khairatkar-Joshi, N; Mukhopadhyay, I; Raghuram, A; Rao, SS; Sangana, RR; Thomas, A; Vaiyapuri, TS; Wale, DP, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
piperazines
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.68400.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency6.00810.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency11.98770.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency6.00810.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 1Rattus norvegicus (Norway rat)IC50 (µMol)0.00510.00040.21474.0000AID218485; AID218486; AID266314; AID266315; AID313136; AID313137; AID313140; AID313141; AID763712; AID763713
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)0.00040.00040.764912.5000AID266314
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)1.00000.00091.901410.0000AID576612
Transient receptor potential cation channel subfamily M member 8Homo sapiens (human)IC50 (µMol)0.63750.02001.27553.9000AID1410815; AID779486
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)IC50 (µMol)0.01190.00020.606010.0000AID1066646; AID1177525; AID1272985; AID1373241; AID1399071; AID1481479; AID1498465; AID1567462; AID1691522; AID242439; AID242493; AID313134; AID313135; AID313138; AID313139; AID387153; AID470070; AID779485
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)Ki0.00580.00010.67956.4000AID1451859; AID1451870; AID1744410
Transient receptor potential cation channel subfamily M member 8Rattus norvegicus (Norway rat)IC50 (µMol)0.47500.05802.65048.3000AID1289986
Transient receptor potential cation channel subfamily M member 8Mus musculus (house mouse)IC50 (µMol)0.40000.40003.06679.0000AID1177522; AID1177523
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)4.50000.00033.166210.0000AID470071
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (115)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
positive regulation of cold-induced thermogenesisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
fever generationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
microglial cell activationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
diet induced thermogenesisTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
peptide secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of systemic arterial blood pressureTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
lipid metabolic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chemosensory behaviorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of heart rateTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of mitochondrial membrane potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
glutamate secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to heatTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of apoptotic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to peptide hormoneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
behavioral response to painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
sensory perception of mechanical stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory postsynaptic potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
smooth muscle contraction involved in micturitionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to alkaloidTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to ATPTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to tumor necrosis factorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to acidic pHTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to temperature stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of establishment of blood-brain barrierTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to capsazepineTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to nerve growth factor stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
ligand-gated calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
transmembrane signaling receptor activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
voltage-gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calmodulin bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
ATP bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chloride channel regulator activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphatidylinositol bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
metal ion bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphoprotein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
temperature-gated ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulum membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
membrane raftTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
dendritic spine membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
neuronal cell bodyTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
postsynaptic membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (116)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID763712Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of capsaicin-induced calcium flux after 30 mins by Fluo-4AM based fluorescence assay2013European journal of medicinal chemistry, Aug, Volume: 66Design and synthesis of conformationally restricted capsaicin analogues based in the 1, 3, 4-thiadiazole heterocycle reveal a novel family of transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID1177526Antagonist activity against human TRPA1 expressed in T-REx HEK cells assessed as inhibition of AITC-induced increase in intracellular Ca2+ accumulation pre-incubated for 3 mins prior to AITC stimulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID1066637Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of cold-induced intracellular Ca2+ influx by Fluo-8 AM staining-based fluorescence analysis2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID313135Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by [45Ca2+] uptake assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID266314Antagonist activity against capsaicin-induced 45calcium ion uptake in CHO cells expressing rat TRPV12006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
AID1373244Antinociceptive activity in heat-induced pain mouse model assessed as increase in tail-flick latency at 30 mg/kg pretreated for 30 mins followed by acetic acid challenge measured for 12 secs post acetic acid challenge by tail-flick test2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
AID1691525Analgesic activity in acetic acid-induced rat model of abdominal constriction assessed as reduction in number of writhes at 30 mg/kg, po administered as single dose2020European journal of medicinal chemistry, May-15, Volume: 194Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
AID313144Oral bioavailability in rat2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID1177525Antagonist activity against human TRPV1 expressed in T-REx HEK cells assessed as inhibition of capsaicin-induced increase in intracellular Ca2+ accumulation pre-incubated for 3 mins prior to capsaicin stimulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID1272990Analgesic activity in heat-induced KM mouse pain model assessed as delay in tail-filck response at 30 mg/kg, po2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.
AID1177524Antagonist activity against mouse TRPM8 expressed in T-REx HEK cells assessed as inhibition of cold-induced increase in intracellular Ca2+ accumulation pre-incubated for 3 mins prior to cold stimulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID1691519Induction of hyperthermia in rat assessed as change in body temperature at 30 mg/kg, po administered as single dose measured after 30 to 60 mins by rectal thermometric method2020European journal of medicinal chemistry, May-15, Volume: 194Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
AID1691526Analgesic activity in rat assessed as increase in tail flick latency at 30 mg/kg, po administered as single dose by tail-flick test2020European journal of medicinal chemistry, May-15, Volume: 194Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
AID763714Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of capsaicin-induced calcium flux at 1 uM after 30 mins by Fluo-4AM based fluorescence assay relative to control2013European journal of medicinal chemistry, Aug, Volume: 66Design and synthesis of conformationally restricted capsaicin analogues based in the 1, 3, 4-thiadiazole heterocycle reveal a novel family of transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID1177519Agonist activity at human TRPV1 expressed in T-REx HEK cells assessed as increase in intracellular Ca2+ accumulation by Fluo-4 AM dye based fluorescence assay relative to ionomycin2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID763715Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of temperature-induced calcium flux at 1 uM after 30 mins by Fluo-4AM based fluorescence assay relative to control2013European journal of medicinal chemistry, Aug, Volume: 66Design and synthesis of conformationally restricted capsaicin analogues based in the 1, 3, 4-thiadiazole heterocycle reveal a novel family of transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID313139Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as blockade of acid-induced receptor activation by FLIPR assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID266315Antagonist activity against acid-induced 45calcium ion uptake in CHO cells expressing rat TRPV1 at pH52006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
AID1373241Antagonist activity at human TRPV1 assessed as inhibition of capsaicin-induced intracellular calcium level preincubated for 2.5 mins followed by capsaicin addition measured for 5 mins by aequorin dye based assay2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
AID1066642Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of icilin-induced intracellular Ca2+ influx at 0.3 to 10 uM by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID1289986Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol mediated current amplitude at +80 mV holding potential by whole cell patch-clamp assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.
AID1691523Antagonist activity at human TRPV1 assessed as inhibition of pH 5-induced channel activation at 10 uM relative to control2020European journal of medicinal chemistry, May-15, Volume: 194Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
AID10772Plasma clearance in rat by iv administration at a dose of 3 mg/kg2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID1451859Displacement of [3H]RTX from human TRPV1 expressed in CHO cell membranes after 45 mins by scintillation counting method2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1).
AID1177518Agonist activity at human TRPV1 expressed in T-REx HEK cells assessed as increase in intracellular Ca2+ accumulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID1177516Agonist activity at mouse TRPM8 expressed in T-REx HEK cells assessed as increase in intracellular Ca2+ accumulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID1272989Analgesic activity in proton-induced KM mouse pain model assessed as suppression of acetic acid-induced writhing response at 30 mg/kg, po dosed 30 mins before acetic acid challenge2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.
AID1567462Antagonist activity at capsaicin-induced human recombinant TRPV1 expressed in CHO-K1 cells co-expressing aequorin incubated for 2.5 mins in presence of ATP followed by capsaicin addition by luminescence assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1410815Antagonist activity at TRPM8 (unknown origin) assessed as reduction in menthol-induced calcium influx2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity.
AID1567482Antinociceptive activity in KM mouse model of acetic acid induced pain assessed as suppression of writhes at 1 to 10 mg/kg, po administered as single dose pretreated for 30 mins followed by acetic acid challenge and measured for 15 mins2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1066628Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of proton-induced intracellular Ca2+ influx at 10 uM by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID1177523Antagonist activity against mouse TRPM8 expressed in T-REx HEK cells assessed as inhibition of icilin-induced increase in intracellular Ca2+ accumulation pre-incubated for 3 mins prior to icilin stimulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID1272988Analgesic activity in capsaicin-induced KM mouse assessed as reduction in paw licking time at 30 mg/kg, po dosed 30 mins before capsaicin challenge2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.
AID1066645Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of menthol-induced intracellular Ca2+ influx by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID10896Tmax in rat by po administration at a dose of 40 mg/kg2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID1567483Antinociceptive activity in KM mouse model of thermal-induced nociception assessed as increase in latency to tail withdrawal at 1 to 10 mg/kg, po administered as single dose pretreated for 30 mins2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1567461Effect on body temperature in KM mouse assessed as increase in rectal temperature at 10 mg/kg, po administered as single dose measured every 30 mins for 120 mins by electric probe thermometer2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID237660In vivo clearance of compound after intravenous administration in rats at concentration of 3 mg/kg was determined2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
AID1177521Agonist activity at human TRPA1 expressed in T-REx HEK cells assessed as increase in intracellular Ca2+ accumulation by Fluo-4 AM dye based fluorescence assay relative to ionomycin2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID1373243Antinociceptive activity in proton-induced pain mouse model assessed as reduction in acetic acid-induced writhes at 30 mg/kg pretreated for 30 mins followed by acetic acid challenge measured for 15 mins post acetic acid challenge2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
AID1066646Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of CAP-induced intracellular Ca2+ influx by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID763713Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of temperature-induced calcium flux after 30 mins by Fluo-4AM based fluorescence assay2013European journal of medicinal chemistry, Aug, Volume: 66Design and synthesis of conformationally restricted capsaicin analogues based in the 1, 3, 4-thiadiazole heterocycle reveal a novel family of transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID387155Analgesic activity against complete Freund's adjuvant-induced thermal hyperalgesia in po dosed Sprague-Dawley rat assessed as paw withdrawal latency2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID1066654Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of heat-induced intracellular Ca2+ influx measured for 42 mins by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID1744410Antagonist activity at human TRPV1 expressed in HEK cells assessed as inhibition of 10 nM capsaicin-induced calcium uptake by FLIPR assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift.
AID1177520Agonist activity at human TRPA1 expressed in T-REx HEK cells assessed as increase in intracellular Ca2+ accumulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID470071Antagonist activity at human TRPA1 expressed in HEK293 cells assessed as decrease in intracellular calcium level2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID11490Pharmacokinetic (PK) parameter Vz in rat2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID1875056Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced intracellular calcium accumulation preincubated with compound followed by capsaicin addition and measured at 180 sec by fluorescence based microplate
AID1373242Aqueous solubility of the compound2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
AID1177522Antagonist activity against mouse TRPM8 expressed in T-REx HEK cells assessed as inhibition of menthol-induced increase in intracellular Ca2+ accumulation pre-incubated for 3 mins prior to menthol stimulation by Fluo-4 AM dye based fluorescence assay2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID313138Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as blockade of capsaicin-induced receptor activation by FLIPR assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID1272992Toxicity in KM mouse assessed as hyperthermia at 30 mg/kg, ig measured from 30 to 90 mins by electric probe thermometric analysis relative to vehicle-treated control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.
AID387156Antinociceptive activity against hyperalgesia in po dosed rat Chung neuropathic pain model2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID1567463Antagonist activity at low pH-induced human recombinant TRPV1 expressed in CHO-K1 cells co-expressing aequorin at 50 uM incubated for 2.5 mins in presence of ATP followed by hydrochloride addition at pH 5 by luminescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1066653Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of proton-induced intracellular Ca2+ influx at 100 uM by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID470068Inhibition of FAAH-mediated hydrolysis of [3H]AEA in rat brain membrane2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID1498465Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cell membranes after 60 mins by scintillation counting method2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists.
AID218485Vanilloid receptor subtype 1 antagonist activity based on its ability to block capsaicin-induced (CAP) activation of the rat VR1 channel in a HEK293 cell line2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID242493Inhibition of human vanilloid receptor 1 in HEK293 cells in capsaicin-induced FLIPR assay2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
AID1392653Toxicity in C57BL/6 mouse assessed as change in body temperature at 3 mg/kg, iv after 120 mins2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
AID763711Antagonist activity at chicken TRPV1 receptor assessed as inhibition of capsaicin-induced calcium flux at 1 uM after 30 mins by cell based Fluo-4AM fluorescence assay relative to control2013European journal of medicinal chemistry, Aug, Volume: 66Design and synthesis of conformationally restricted capsaicin analogues based in the 1, 3, 4-thiadiazole heterocycle reveal a novel family of transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID1875055Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced intracellular calcium accumulation at 100 nM preincubated with compound followed by capsaicin addition and measured at 180 sec by fluorescence based m
AID1289989Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol mediated current amplitude at 3 uM at +80 mV holding potential measured after drug wash out by whole cell patch-clamp assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.
AID218460Antagonistic activity against vanilloid receptor 1 (TRPV1)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?
AID1066644Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of icilin-induced intracellular Ca2+ influx by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID1451870Displacement of [3H]MPOU from human TRPV1 expressed in CHO cell membranes after 45 mins by scintillation counting method2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1).
AID237303In vivo half life of compound after intravenous administration in rats at concentration of 3 mg/kg was determined2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
AID237952Rat liver metabolic stability was determined2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
AID1567481Antinociceptive activity in KM mouse model of capsaicin-induced pain assessed as reduction in paw licking time at 1 to 10 mg/kg, po administered as single dose pretreated for 30 mins followed by capsaicin challenge and measured for 5 mins2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1177517Agonist activity at mouse TRPM8 expressed in T-REx HEK cells assessed as increase in intracellular Ca2+ accumulation by Fluo-4 AM dye based fluorescence assay relative to ionomycin2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Identification of Indole Alkaloid Structural Units Important for Stimulus-Selective TRPM8 Inhibition: SAR Study of Naturally Occurring Iboga Derivatives.
AID779486Inhibition of TRPM8 (unknown origin)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides as TRPM8 antagonists.
AID237790In vivo volume of distribution of compound after intravenous administration in rats at concentration of 3 mg/kg was determined2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
AID313137Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by [45Ca2+] uptake assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID1567475Antinociceptive activity in KM mouse model of acetic acid induced pain assessed as suppression of writhes at 30 mg/kg, po administered as single dose pretreated for 30 mins followed by acetic acid challenge and measured for 15 mins2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID470069Inhibition of FAAH-mediated hydrolysis of [3H]AEA in rat brain membrane at 50 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID1272985Antagonist activity at capsaicin-stimulated human TRPV1 receptor in aequorin expressing cells preincubated for 2.5 mins followed by capsaicin addition2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.
AID1481479Antagonist activity at recombinant human TRPV1 expressed in CHO cells assessed as inhibition of capsaicin-induced activation2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Pharmacological evaluation of novel (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives as TRPV4 antagonists for the treatment of pain.
AID313134Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID779485Inhibition of TRPV1 (unknown origin)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides as TRPM8 antagonists.
AID313141Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as blockade of acid-induced receptor activation by FLIPR assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID387154Ratio of drug level in brain to plasma in po dosed Sprague-Dawley rat2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID236064Bioavailability in rat (single dose 30 mg/kg p.o.)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists.
AID1272987Inhibition of ovine COX1 at 10 uM by enzyme immunoassay2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.
AID1567479Effect on body temperature in KM mouse assessed as increase in rectal temperature at 30 mg/kg, po administered as single dose measured every 30 mins for 90 mins by electric probe thermometer2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1875053Agonist activity at human TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium accumulation by measuring efficacy at 100 nM measured at 180 sec by fluorescence based microplate reader analysis relative to capsaicin
AID313136Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID1399075Aqueous solubility of the compound incubated for 72 hrs under shaking condition by HPLC method2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1.
AID1495475Antinociceptive activity in Kunming mouse model of thermal-induced nociception assessed as increase in latency to tail withdrawal at 60 mg/kg, po by tail flick test2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
AID12648Half life period in rat by iv administration at a dose of 3 mg/kg2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID11432Cmax in rat by po administration at a dose of 40 mg/kg2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID1567476Antinociceptive activity in KM mouse model of thermal-induced nociception assessed as increase in latency to tail withdrawal at 30 mg/kg, po administered as single dose pretreated for 30 mins2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1399071Inhibition of human TRPV1 expressed in HEK293 cells assessed as reduction in capsaicin-induced activity pretreated for 2.5 mins followed by capsaicin addition measured immediately in presence of coelenterazine h2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1.
AID1691522Antagonist activity at human TRPV1 assessed as inhibition of capsaicin-induced channel activation2020European journal of medicinal chemistry, May-15, Volume: 194Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
AID242439Inhibition of human vanilloid receptor 1 in HEK293 cells in pH 5.5-induced FLIPR assay2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
AID1567474Antinociceptive activity in KM mouse model of capsaicin-induced pain assessed as reduction in paw licking time at 30 mg/kg, po administered as single dose pretreated for 30 mins followed by capsaicin challenge and measured for 5 mins2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
AID1272986Inhibition of human recombinant COX2 at 10 uM by enzyme immunoassay2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.
AID13439Oral bioavailability in rat by po administration at a dose of 40 mg/kg2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1481466Antagonist activity at recombinant human TRPV4 expressed in CHOK1 cells assessed as inhibition of 4alphaPDD-induced activation pretreated for 5 mins followed by 4alphaPDD stimulation measured for 5 mins by FLIPR assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Pharmacological evaluation of novel (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives as TRPV4 antagonists for the treatment of pain.
AID218486Vanilloid receptor subtype 1 antagonist activity based on its ability to block low pH-induced activation of the rat VR1 channel in a HEK293 cell line2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
AID1875052Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced intracellular calcium accumulation at 10 uM preincubated with compound followed by capsaicin addition and measured at 180 sec by fluorescence based mi
AID313140Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as blockade of capsaicin-induced receptor activation by FLIPR assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
AID1691524Analgesic activity in capsaicin-induced rat model of hyperalgesia assessed as reduction in total paw licking time at 30 mg/kg, po administered as single dose2020European journal of medicinal chemistry, May-15, Volume: 194Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
AID1289988Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol mediated current amplitude at 3 uM at +80 mV holding potential by whole cell patch-clamp assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.
AID470070Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as decrease in intracellular calcium level2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID387153Antagonist activity at human recombinant TRPV1 expressed in human 1321N1 cells assessed as inhibition of capsaicin-induced calcium influx by FLIPR assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
AID244059Percent inhibition of human ether-a-go-go related gene (hERG) channel expressed in HEK293 cells in standard whole cell voltage-clamp assay2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
AID1346617Human TRPV1 (Transient Receptor Potential channels)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides as TRPM8 antagonists.
AID1346643Rat TRPV1 (Transient Receptor Potential channels)2003The Journal of pharmacology and experimental therapeutics, Jul, Volume: 306, Issue:1
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
AID493017Wombat Data for BeliefDocking2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (82)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's28 (34.15)29.6817
2010's49 (59.76)24.3611
2020's5 (6.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.17 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.20%)5.53%
Reviews2 (2.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other80 (96.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]